SpicyIP Tidbit: Roche opposed yet again.


Just when we thought it couldn’t get any better, the patent scene in India seems to be heating up, yet again. Roche’s anti-infection drug for HIV/ AIDS and organ transplant patients, Valcyte faces yet another opposition after its tumultuous past in the USPTO.

After going past the pre-grant stage without hearing an opposition by two NGOs (Indian Network for People Living with HIV/AIDS and the Tamil Nadu Networking People with HIV/AIDS), Ranbaxy has now filed a post-grant opposition, claiming that the drug has not proved enhanced efficacy than what is already known- as is required under current Indian Law.

Last heard, CIPLA may jump on to this bandwagon, and file for post-grant opposition as well, and Lawyer’s Collective was to contest the same in the Madras High Court.

Leave a Reply

Your email address will not be published.